Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples
Using the enzymatic methylation sequencing methods described, we report a putative link of interleukin (IL)-15 methylation changes to acalabrutinib treatment response in a CLL clinical trial cohort (ACE-CL-001 trial, NCT02029443).
Authors
- Steven W. Criscione (ORCID: https://orcid.org/0000-0002-6550-5769)
- Maurizio Scaltriti (ORCID: https://orcid.org/0000-0002-5522-1447)
- Pablo Cingolani (ORCID: https://orcid.org/0000-0003-1553-0920)
- Richard R. Furman (ORCID: https://orcid.org/0000-0003-1677-7626)
- Barrett Nuttall (ORCID: https://orcid.org/0000-0002-0362-229X)
- Jennifer R. Brown (ORCID: https://orcid.org/0000-0003-2040-4961)
- Елена Бибикова
- Veerendra Munugalavadla (ORCID: https://orcid.org/0000-0002-2390-3822)
- Kerrin Mendler (ORCID: https://orcid.org/0000-0002-0101-8451)
- J. Carl Barrett (ORCID: https://orcid.org/0000-0003-4462-2955)
- Kathleen A. Burke (ORCID: https://orcid.org/0009-0005-7256-0255)
- Andrew Mortlock (ORCID: https://orcid.org/0009-0001-3858-5804)
- Daniel Karl
- James Hadfield (ORCID: https://orcid.org/0000-0001-9868-4989)
- Megan Callahan
- Brian Dougherty (ORCID: https://orcid.org/0000-0002-0093-1142)
- Serhiy Naumenko
- John C. Byrd
Institutions
- Cornell University (US)
- AstraZeneca (South Korea) (KR)
- Newborn Screening Ontario (CA)
- Precision BioSciences (United States) (US)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- Dana-Farber Cancer Institute (US)
- AstraZeneca (United States) (US)
- The Ohio State University (US)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1186/s13148-025-01959-0
- Citations
- 2
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- AstraZeneca